KR102115060B1 - N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도 - Google Patents

N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도 Download PDF

Info

Publication number
KR102115060B1
KR102115060B1 KR1020157017192A KR20157017192A KR102115060B1 KR 102115060 B1 KR102115060 B1 KR 102115060B1 KR 1020157017192 A KR1020157017192 A KR 1020157017192A KR 20157017192 A KR20157017192 A KR 20157017192A KR 102115060 B1 KR102115060 B1 KR 102115060B1
Authority
KR
South Korea
Prior art keywords
propyl
sulfate
disease
pharmaceutically acceptable
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157017192A
Other languages
English (en)
Korean (ko)
Other versions
KR20150105313A (ko
Inventor
스테판 불렛
세실리아 이스트렐라
마티유 바리엘
패트리샤 멜니크
니콜라스 서긴트
뤽 뷰이
필립 벨웨어드
Original Assignee
알즈프로텍트
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
위니베르시떼 드 릴르 2 드루아 에 상떼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알즈프로텍트, 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 위니베르시떼 드 릴르 2 드루아 에 상떼 filed Critical 알즈프로텍트
Publication of KR20150105313A publication Critical patent/KR20150105313A/ko
Application granted granted Critical
Publication of KR102115060B1 publication Critical patent/KR102115060B1/ko
Assigned to 위니베르시떼 드 릴르 reassignment 위니베르시떼 드 릴르 권리지분의 전부이전등록 Assignors: 위니베르시떼 드 릴르 2 드루아 에 상떼
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157017192A 2012-12-27 2013-12-27 N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도 Active KR102115060B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP12306690.4 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
KR20150105313A KR20150105313A (ko) 2015-09-16
KR102115060B1 true KR102115060B1 (ko) 2020-05-25

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017192A Active KR102115060B1 (ko) 2012-12-27 2013-12-27 N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도

Country Status (23)

Country Link
US (3) US9562018B2 (https=)
EP (1) EP2938597B1 (https=)
JP (1) JP6384923B2 (https=)
KR (1) KR102115060B1 (https=)
CN (1) CN105008333B (https=)
AU (2) AU2013369288B2 (https=)
BR (1) BR112015015474B1 (https=)
CA (1) CA2895285C (https=)
DK (1) DK2938597T3 (https=)
ES (1) ES2605494T3 (https=)
HR (1) HRP20161612T2 (https=)
HU (1) HUE030930T2 (https=)
IL (1) IL239450B (https=)
LT (1) LT2938597T (https=)
MX (1) MX363367B (https=)
NZ (1) NZ708959A (https=)
PL (1) PL2938597T3 (https=)
PT (1) PT2938597T (https=)
RS (1) RS55511B1 (https=)
RU (1) RU2655454C2 (https=)
SI (1) SI2938597T1 (https=)
WO (1) WO2014102339A1 (https=)
ZA (1) ZA201504521B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2938597T (lt) 2012-12-27 2017-01-25 Alzprotect N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
JP2023543630A (ja) * 2020-10-01 2023-10-17 アルツプロテクト Ｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミンのコハク酸塩、それらの調製及びそれらの使用
US20230364076A1 (en) * 2020-10-07 2023-11-16 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
CN118524838A (zh) 2021-12-20 2024-08-20 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺琥珀酸盐及其溶剂合物用于治疗运动神经元疾病和神经肌肉接头病症的用途
CN118946356A (zh) 2022-03-25 2024-11-12 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的盐及其溶剂化物用于治疗感觉神经元疾病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051489A1 (en) 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
US20050020582A1 (en) * 2001-05-25 2005-01-27 Prusiner Stanley B Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
LT2938597T (lt) * 2012-12-27 2017-01-25 Alzprotect N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051489A1 (en) 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Berge 외. Journal of Pharmaceutical Sciences. Vol. 66(1), 1977, pp. 1-19

Also Published As

Publication number Publication date
AU2013369288A1 (en) 2015-07-02
RS55511B1 (sr) 2017-05-31
CA2895285C (en) 2021-03-30
HUE030930T2 (hu) 2017-06-28
CN105008333A (zh) 2015-10-28
BR112015015474A2 (https=) 2017-08-15
DK2938597T3 (en) 2017-01-09
US10772884B2 (en) 2020-09-15
RU2655454C2 (ru) 2018-05-29
JP2016503813A (ja) 2016-02-08
US9562018B2 (en) 2017-02-07
HRP20161612T1 (hr) 2017-01-27
ES2605494T3 (es) 2017-03-14
RU2015130671A (ru) 2017-01-30
SI2938597T1 (sl) 2017-03-31
NZ708959A (en) 2019-11-29
EP2938597A1 (en) 2015-11-04
ZA201504521B (en) 2016-11-30
AU2018202218B2 (en) 2019-02-21
AU2013369288A8 (en) 2015-07-16
US20170151235A1 (en) 2017-06-01
IL239450B (en) 2018-06-28
JP6384923B2 (ja) 2018-09-05
LT2938597T (lt) 2017-01-25
US20160108003A1 (en) 2016-04-21
WO2014102339A1 (en) 2014-07-03
MX2015008502A (es) 2015-12-16
PT2938597T (pt) 2016-12-09
CA2895285A1 (en) 2014-07-03
MX363367B (es) 2019-03-20
AU2018202218A1 (en) 2018-04-26
CN105008333B (zh) 2018-02-09
KR20150105313A (ko) 2015-09-16
IL239450A0 (en) 2015-07-30
BR112015015474B1 (pt) 2022-04-19
AU2013369288B2 (en) 2018-02-22
US20190381036A1 (en) 2019-12-19
HK1215582A1 (en) 2016-09-02
US10537569B2 (en) 2020-01-21
EP2938597B1 (en) 2016-10-26
HRP20161612T2 (hr) 2017-02-24
PL2938597T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
KR102115060B1 (ko) N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도
ES2652187T3 (es) Fenilacetato de l-ornitina y métodos para elaborar el mismo
US9796673B2 (en) L-tartrate salt of pridopidine
EP4353723A1 (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
JP7212958B2 (ja) バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
WO2013134371A1 (en) Methods and compounds to be used in the treatment of neurodegenerative diseases
ES2587064T3 (es) Sales fumarato novedosas de un antagonista del receptor de histamina H3
JP2013529224A (ja) 結晶性エザチオスタット塩酸塩非溶媒和物
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
HK1215582B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US20240025868A1 (en) Phenothiazine compounds for the treatment of alzheimer's disease and other age-related and neurological diseases
WO2026023672A1 (ja) （２Ｒ）－Ｎ－ベンジル－１－［５－（２－フルオロプロパン－２－イル）－７－オキソ－６，７－ジヒドロ［１，３］チアゾロ［５，４－ｄ］ピリミジン－２－イル］ピロリジン－２－カルボキサミドの新規結晶、およびその製造方法
WO2024009977A1 (ja) ５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶
HK40111001A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2023153422A1 (ja) シクロヘキセノン化合物の結晶形
ITMI20131839A1 (it) Co-cristallo di un farmaco antidepressivo

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181023

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191029

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200423

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200519

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200519

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230510

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240513

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250513

Start annual number: 6

End annual number: 6